RK-33|RK33|DDX3 inhibitor

RK-33|RK33|DDX3 inhibitor

RK-33 is a novel DDX3 inhibitor for lung cancer therapy.

Product Name: RK-33|Cat No. DC9761|CAS: 1070773-09-9|Other names:RX33, RX 33|MW: 428.16|Molecule Formular: C23H20N6O3|Purity>98%

RK-33 is a novel DDX3 inhibitor for lung cancer therapy. RK-33 binds to DDX3 and abrogates its activity. Inhibition of DDX3 by RK-33 caused G1 cell cycle arrest, induced apoptosis, and promoted radiation sensitization in DDX3-overexpressing cells. Importantly, RK-33 in combination with radiation induced tumor regression in multiple mouse models of lung cancer. Mechanistically, loss of DDX3 function either by shRNA or by RK-33 impaired Wnt signaling through disruption of the DDX3-β-catenin axis and inhibited non-homologous end joining-the major DNA repair pathway in mammalian somatic cells.

For research only, not for human use.